Summary | Half of the recent acquisitions among drug makers and
biotechs involved an orphan drug, according to Moody's Investor
Service, which believes the trend will continue.
biotechs involved an orphan drug, according to Moody's Investor
Service, which believes the trend will continue.
blogs.wsj.com | 29 May 2015